Deirdre Landsberg is a clinical pharmacist with an interest in the translation of pharmacogenomics to clinical practice. Deirdre is currently undertaking her PhD examining the clinical application of DPYD genotype screening to guide dosing of fluoropyrimidines in cancer patients. Deridre is also currently employed as a pharmacogenomics pharmacist at the Women’s and Children’s Hospital (Adelaide, Australia) working under the MARVEL-PIC study, which aims to use pre-emptive pharmacogenomic testing to guide the prescribing of supportive care medicines in paediatric oncology patients.

Dr Janet Coller is the co-head of the Clinical Pharmacogenomics Laboratory in the Discipline of Pharmacology, School of Pharmacy and Biomedical Sciences, College of Health at the Adelaide University. She has been active in the field of pharmacogenetics, focusing on drug metabolism and treatment responses, since completion of her PhD in Medicine at the University of Adelaide. Her research interests have expanded to encompass the emerging field of immunogenetics that has implications for therapeutics in several fields including cancer. In particular, Dr Coller’s research simultaneously investigates the cumulative impact of pharmaco- and immuno- genetics, treatment and patient characteristics to predicting clinical outcomes for each individual patient in an attempt to achieve more personalised treatment approaches.

Britto is a second-year PhD candidate at Flinders University (Adelaide, South Australia) whose research focuses on the human trace amine-associated receptor 1 (TAAR1). His work employs experimental and computational approaches to investigate structure-function relationships and signalling mechanisms of TAAR1, including the impact of genetic variants. He also has a strong interest in compound screening and the characterisation of novel TAAR1-targeting compounds. His research to date has contributed to peer-reviewed publications and ongoing manuscripts that explore the molecular basis of TAAR1 function and its relevance to neuropsychiatric disorders.

Dr. Dilanka Fernando is a Postdoctoral Research Fellow at the Monash Institute of Pharmaceutical Sciences (MIPS) in Australia. He earned his PhD in Biochemistry and Molecular Biology from Monash University in 2020 and has since continued his research there. His work focuses on the pharmacology and structural biology of the calcium-sensing receptor (CaSR), a clinically important G protein–coupled receptor that plays a central role in calcium homeostasis and numerous disease states. Dr. Fernando investigates disease-associated CaSR mutations through detailed functional and structural characterisation to elucidate their effects on receptor signalling, ligand recognition, and disease mechanisms. By integrating biochemical, pharmacological, and structural approaches, his work aims to support the development of novel therapeutics for CaSR-related disorders. He has shared his findings through publications in peer-reviewed journals and presentations at national and international conferences. At MIPS, Dr. Fernando contributes to multidisciplinary drug discovery programs by bridging fundamental receptor biology with translational pharmaceutical science.

Dr. Julian Peter Müller is a postdoctoral researcher at the Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Germany. His research focuses on the variability in drug metabolism driven by genetic and non-genetic factors. He is developing and applying methods to phenotype drug metabolism in patients with the aim of improving the safety and efficacy of pharmacotherapy. To support this work, Dr. Müller employs liquid chromatography coupled to tandem mass spectrometry to quantify drugs, drug metabolites, and endogenous biomarkers of drug metabolism in human biomaterials. Recently, he has worked on the characterization and application of solanidine and its metabolites as biomarkers for the activity of the important drug-metabolizing enzyme CYP2D6, as well as on methods to phenotype CYP2C19.

Noora Kulla is a doctoral researcher with a professional background in pharmacy and a research focus on pharmacogenomics. Prior to entering academia, she worked for over a decade as a community pharmacist, where gaining deep insight into real-world drug therapy and patient care. She holds a Master’s degree in Drug Discovery and Development and is currently pursuing her PhD, focusing on implementation of pharmacogenetics in Finland, its current status, benefits and future prospects. Her work aims to advance individualized, evidence-based drug therapy supported by pharmacogenetics, and to understand the perspectives of both patients and healthcare professionals. In addition to research, she is actively involved in science communication and professional development. She serves as the Communications Officer for the Finnish Society of Clinical Pharmacology and contributes to inter-European research collaboration through her role in the EACPT Early Career Clinical Pharmacologists focus group on Pharmacogenetics and Personalized Medicine.